{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:59:22Z","timestamp":1786996762124,"version":"build-2736575974"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T00:00:00Z","timestamp":1695686400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.semarthrit.2023.152264","type":"journal-article","created":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T11:32:08Z","timestamp":1695727928000},"page":"152264","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Burden of adult-onset Still's disease: A systematic review of health-related quality of life, utilities, costs and resource use"],"prefix":"10.1016","volume":"63","author":[{"given":"Piero","family":"Ruscitti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugen","family":"Feist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviam","family":"Canon-Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilde","family":"Rabijns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Toennessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Bartlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Gregg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"McGonagle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2023.152264_bib0001","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1136\/ard.2005.042143","article-title":"Diagnosis and management of adult onset Still's disease","volume":"65","author":"Efthimiou","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2023.152264_bib0002","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jaut.2018.07.018","article-title":"A comprehensive review on adult onset Still's disease","volume":"93","author":"Giacomelli","year":"2018","journal-title":"J Autoimmun"},{"issue":"10","key":"10.1016\/j.semarthrit.2023.152264_bib0003","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41584-018-0081-x","article-title":"Mechanisms, biomarkers and targets for adult-onset Still's disease","volume":"14","author":"Feist","year":"2018","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2023.152264_bib0004","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.semarthrit.2021.06.004","article-title":"Adult-onset Still's disease in focus: clinical manifestations, diagnosis, treatment, and unmet needs in the era of targeted therapies","volume":"51","author":"Efthimiou","year":"2021","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152264_bib0005","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13075-019-1838-6","article-title":"Adult-onset Still's disease biological treatment strategy may depend on the phenotypic dichotomy","volume":"21","author":"Vercruysse","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"10.1016\/j.semarthrit.2023.152264_bib0006","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.autrev.2014.08.032","article-title":"Adult onset Still's disease (AOSD) in the era of biologic therapies: dichotomous view for cytokine and clinical expressions","volume":"13","author":"Maria","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"7","key":"10.1016\/j.semarthrit.2023.152264_bib0007","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1002\/art.40865","article-title":"Treatment to target using recombinant interleukin-1 receptor antagonist as first-line monotherapy in new-onset systemic juvenile idiopathic arthritis: results from a five-year follow-up study","volume":"71","author":"Ter Haar","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152264_bib0008","first-page":"12455","article-title":"The joint involvement in adult onset Still's disease is characterised by a peculiar magnetic resonance imaging and a specific transcriptomic profile","volume":"11","author":"Ruscitti","year":"2021","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.semarthrit.2023.152264_bib0009","doi-asserted-by":"crossref","first-page":"4844","DOI":"10.1093\/rheumatology\/keaa904","article-title":"Dissecting the clinical heterogeneity of adult-onset Still's disease: results from a multi-dimensional characterization and stratification","volume":"60","author":"Berardicurti","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152264_bib0010","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3109\/07853890.2014.971052","article-title":"Adult-onset Still's disease-pathogenesis, clinical manifestations, and new treatment options","volume":"47","author":"Kadavath","year":"2015","journal-title":"Ann Med"},{"key":"10.1016\/j.semarthrit.2023.152264_bib0011","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.clim.2016.05.010","article-title":"Cytokine profile in adult-onset Still's disease: comparison with systemic juvenile idiopathic arthritis","volume":"169","author":"Inoue","year":"2016","journal-title":"Clin Immunol"},{"issue":"1\u20132","key":"10.1016\/j.semarthrit.2023.152264_bib0012","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s12026-014-8561-9","article-title":"Pathogenesis of adult-onset Still's disease: new insights from the juvenile counterpart","volume":"61","author":"Jamilloux","year":"2015","journal-title":"Immunol Res"},{"key":"10.1016\/j.semarthrit.2023.152264_bib0013","article-title":"Adult-onset Still's disease","year":"2021","journal-title":"NORD"},{"issue":"12","key":"10.1016\/j.semarthrit.2023.152264_bib0014","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10122633","article-title":"Clinical phenotypes of adult-onset Still's disease: new insights from pathophysiology and literature findings","volume":"10","author":"Mitrovic","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.semarthrit.2023.152264_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2022.152139","article-title":"Systematic review on the use of biologics in adult-onset still's disease","volume":"58","author":"Fautrel","year":"2023","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2023.152264_bib0016","unstructured":"Higgins J.P.T., Thomas J., Chandler J., Cumpston M., Li T., Page M.J., et\u00a0al., editors. Cochrane handbook for systematic reviews of interventions [version 6.2] [updated 2021]. https:\/\/training.cochrane.org\/handbook\/current: The Cochrane Collaboration; 2021."},{"key":"10.1016\/j.semarthrit.2023.152264_bib0017","series-title":"Undertaking systematic reviews of research on effectiveness: CRD's guidance for those carrying out or commissioning reviews","author":"Khan","year":"2001"},{"key":"10.1016\/j.semarthrit.2023.152264_bib0018","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.semarthrit.2023.152264_bib0019","series-title":"PROSPERO: international prospective register of systematic reviews","year":"2011"},{"issue":"10","key":"10.1016\/j.semarthrit.2023.152264_bib0020","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.3899\/jrheum.111549","article-title":"Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still's disease. An open, randomized, multicenter study","author":"Nordstr\u00f6m","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152264_bib0021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"10.1016\/j.semarthrit.2023.152264_bib0022","first-page":"72","article-title":"Budget impact analysis of anakinra in the treatment of patients with Still's disease. (2284-24032283-5733)","author":"Ravasio","year":"2020","journal-title":"Italy"},{"key":"10.1016\/j.semarthrit.2023.152264_bib0023","first-page":"91","article-title":"Erratum: budget impact analysis of anakinra in the treatment of patients with Still's disease. (2284-24032283-5733)","author":"Ravasio","year":"2020","journal-title":"Italy"},{"key":"10.1016\/j.semarthrit.2023.152264_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2020.102541","article-title":"Cardiac involvement in adult-onset Still's disease: manifestations, treatments and outcomes in a retrospective study of 28 patients","volume":"116","author":"Bodard","year":"2021","journal-title":"J Autoimmun"},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152264_bib0025","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13054-018-2012-2","article-title":"Diagnostic and management of life-threatening adult-onset Still disease: a French nationwide multicenter study and systematic literature review","volume":"22","author":"Neel","year":"2018","journal-title":"Crit Care"},{"issue":"9","key":"10.1016\/j.semarthrit.2023.152264_bib0026","doi-asserted-by":"crossref","first-page":"4152","DOI":"10.1093\/rheumatology\/keaa899","article-title":"Adult-onset Still's disease with neurological involvement: a single-centre report","volume":"60","author":"Zhao","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.semarthrit.2023.152264_bib0027","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.semarthrit.2019.04.004","article-title":"Racial\/Ethnic variations in morbidity and mortality in adult onset Still's disease: an analysis of national dataset","volume":"49","author":"Mehta","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2023.152264_bib0028","article-title":"Canakinumab treatment in adult-onset Still's disease: case series","author":"Ugurlu","year":"2019","journal-title":"Pediatric Rheumatol"},{"issue":"28","key":"10.1016\/j.semarthrit.2023.152264_bib0029","doi-asserted-by":"crossref","first-page":"e29540","DOI":"10.1097\/MD.0000000000029540","article-title":"Assessment of health-related quality of life in patients with adult onset Still disease: results from a multicentre cross-sectional study","volume":"101","author":"Ruscitti","year":"2022","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"10.1016\/j.semarthrit.2023.152264_bib0030","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/00005792-199103000-00004","article-title":"Adult Still's disease: manifestations, disease course, and outcome in 62 patients","volume":"70","author":"Pouchot","year":"1991","journal-title":"Medicine (Baltimore)"},{"issue":"12","key":"10.1016\/j.semarthrit.2023.152264_bib0031","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1007\/s10067-020-05094-4","article-title":"Anxiety and depression in adult-onset Still's disease patients and associations with health-related quality of life","volume":"39","author":"Chi","year":"2020","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152264_bib0032","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s10067-013-2381-5","article-title":"Tocilizumab for the treatment of adult-onset Still's disease: results from a case series","volume":"33","author":"Cipriani","year":"2014","journal-title":"Clin Rheumatol"},{"issue":"8","key":"10.1016\/j.semarthrit.2023.152264_bib0033","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1136\/annrheumdis-2020-217155","article-title":"Canakinumab for treatment of adult-onset Still's disease to achieve reduction of arthritic manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial","volume":"79","author":"Kedor","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.semarthrit.2023.152264_bib0034","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1136\/annrheumdis-2018-213920","article-title":"Tocilizumab in patients with adult-onset still's disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial","volume":"77","author":"Kaneko","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.semarthrit.2023.152264_bib0035","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1136\/annrheumdis-2021-eular.3968","article-title":"Biologic treatment of adult-onset Still's disease: a single center experience","volume":"80","author":"Yurttas","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.semarthrit.2023.152264_bib0036","first-page":"e10008","article-title":"Adult onset Still's disease: a retrospective, single-center study","volume":"12","author":"Hassan","year":"2020","journal-title":"Cureus"},{"issue":"3","key":"10.1016\/j.semarthrit.2023.152264_bib0037","doi-asserted-by":"crossref","first-page":"e13936","DOI":"10.1111\/ijcp.13936","article-title":"Adult-onset Still's disease and treatment results with tocilizumab","volume":"75","author":"Kir","year":"2021","journal-title":"Int J Clin Pract"},{"issue":"3","key":"10.1016\/j.semarthrit.2023.152264_bib0038","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3109\/14397595.2014.973659","article-title":"The effect of tocilizumab on preventing relapses in adult-onset Still's disease: a retrospective, single-center study","volume":"25","author":"Nishina","year":"2015","journal-title":"Mod Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2023.152264_bib0039","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.semarthrit.2014.05.001","article-title":"The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: a systematic review and meta-analysis","volume":"44","author":"Matcham","year":"2014","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.semarthrit.2023.152264_bib0040","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1007\/s40744-022-00473-6","article-title":"The economic benefit of remission for patients with rheumatoid arthritis","volume":"9","author":"Curtis","year":"2022","journal-title":"Rheumatol Ther"},{"issue":"12","key":"10.1016\/j.semarthrit.2023.152264_bib0041","doi-asserted-by":"crossref","first-page":"4031","DOI":"10.1007\/s00296-010-1529-8","article-title":"Aseptic meningitis in adult onset Still's disease","volume":"32","author":"Akkara Veetil","year":"2012","journal-title":"Rheumatol Int"},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152264_bib0042","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s10067-020-05244-8","article-title":"Neurological manifestations of adult-onset Still's disease-case-based review","volume":"40","author":"Santos","year":"2021","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152264_bib0043","series-title":"Cochrane handbook for systematic reviews of interventions (Version 6.3)","article-title":"Chapter 4: searching for and selecting studies","author":"Lefebvre","year":"2022"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017223001063?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017223001063?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:12:04Z","timestamp":1758733924000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017223001063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":43,"alternative-id":["S0049017223001063"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2023.152264","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Burden of adult-onset Still's disease: A systematic review of health-related quality of life, utilities, costs and resource use","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2023.152264","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152264"}}